MiMedx EBITDA 2010-2025 | MDXG

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

MiMedx ebitda from 2010 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

MiMedx ebitda from 2010 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$243.4B
Amgen (AMGN)	$156.3B
Gilead Sciences (GILD)	$147.7B
Vertex Pharmaceuticals (VRTX)	$100.1B
Bristol Myers Squibb (BMY)	$97.3B
CSL (CSLLY)	$85B
GSK (GSK)	$80B
Regeneron Pharmaceuticals (REGN)	$60B
Alnylam Pharmaceuticals (ALNY)	$58B
Argenex SE (ARGX)	$39.9B
BioNTech SE (BNTX)	$27.1B
Insmed (INSM)	$27B
Royalty Pharma (RPRX)	$20.5B
Biogen (BIIB)	$19.8B
Incyte (INCY)	$16.8B
Illumina (ILMN)	$15.4B
Genmab (GMAB)	$14.7B
Genmab (GNMSF)	$14.3B
Ascendis Pharma (ASND)	$11.7B
BioMarin Pharmaceutical (BMRN)	$11.1B
QIAGEN (QGEN)	$10.9B
Moderna (MRNA)	$10.4B
Exelixis (EXEL)	$10.4B
Swedish Orphan Biovitrum (BIOVF)	$10.3B
Verona Pharma American Depositary Share (VRNA)	$9B
Exact Sciences (EXAS)	$8.5B
Bio-Techne Corp (TECH)	$8.4B
Blueprint Medicines (BPMC)	$8.3B
Roivant Sciences (ROIV)	$8B
Halozyme Therapeutics (HALO)	$7.7B